Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database-Reference-Cited by-同舟云学术

Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database

Published:2018-04-12 Issue:6 Volume:21 Page:622-628
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Bhowmik Debajyoti¹,Hines Dionne M.²,Intorcia Michele³,Wade Rolin L.²

Affiliation:

1. Amgen, Inc., Thousand Oaks, CA, USA;

2. IQVIA, Plymouth Meeting, PA, NC, USA;

3. Amgen (Europe) GmbH, Zug, Switzerland

Funder

Amgen, Inc.

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1457531

Reference30 articles.

1. Multiple Myeloma Research Foundation. What is multiple myeloma? Philadelphia, PA. 1997. www.themmrf.org/multiple-myeloma/what-is-multiple-myeloma/

2. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

3. National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Myeloma. Bethesda, MD. 2016. https://seer.cancer.gov/statfacts/html/mulmy.html

4. Mechanisms of bone lesions in multiple myeloma and lymphoma

5. Metastatic bone disease: clinical features, pathophysiology and treatment strategies

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and risk factors of skeletal-related events in patients with multiple myeloma: A population-based study of Korea;2023-05-18

2. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach;Journal of Bone Oncology;2022-06

3. Evaluación económica de denosumab en la prevención de eventos relacionados con el esqueleto en pacientes con mieloma múltiple en México;Gaceta Mexicana de Oncolog�a;2022-05-26

4. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval;Journal of Bone Oncology;2022-04

5. Discharge status and post-discharge healthcare costs after skeletal-related event hospitalizations among medicare patients with bone metastatic solid tumors or multiple myeloma;Journal of Bone Oncology;2021-02